Ascendis Pharma A/S has announced a significant milestone in its drug development journey. On October 16, 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for TransCon CNP (navepegritide). This drug is intended for the treatment of achondroplasia in children aged two years and older whose epiphyses are not closed.
This development is crucial for Ascendis as it seeks to expand its product offerings in the competitive pharmaceutical market. The final decision from the European Commission (EC) regarding the marketing authorization application (MAA) is expected in the fourth quarter of 2026, which could pave the way for the drug's launch in Germany in the first quarter of 2027 under the brand name YUVIWEL®.
Background
Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with unmet medical needs. The company operates within the pharmaceutical preparations sector, as indicated by its Standard Industrial Classification (SIC) code of 2834. Ascendis is listed on the Nasdaq under the ticker symbol ASND. Recent filings include a series of 6-K forms, with the latest submission being on October 16, 2026.
What the Filing Says
The filing details that the CHMP's positive opinion was based on a comprehensive review of the MAA for TransCon CNP, which included clinical data from three randomized, double-blind, placebo-controlled trials and up to three years of open-label extension data. The EMA will now assess whether the orphan designation for TransCon CNP can be maintained.
Impact
The positive opinion from the CHMP is likely to affect various stakeholders, including patients suffering from achondroplasia, healthcare providers, and investors in the pharmaceutical industry. If authorized, the drug could significantly improve treatment options for affected children and potentially lead to increased revenues for Ascendis Pharma.
What's Next
The next steps involve waiting for the final decision from the European Commission on the marketing authorization application. Ascendis expects this decision to be made in the fourth quarter of 2026, which will determine the future availability of TransCon CNP in the European market.